Pfizer Advances Two Phase 1 Trials Targeting Kidney Disease and Liver Cancer
核心洞察
Pfizer has launched a Phase 1 clinical study for PF-07985631 (搜索), an experimental subcutaneous injection targeting IgA nephropathy (搜索), a kidney disease (搜索) with limited treatment options.
The company is also conducting a Phase 1b/2 trial of PF-08634404 (搜索) for unresectable hepatocellular carcinoma (搜索), testing both monotherapy and combination with ipilimumab.
Both trials represent Pfizer's strategic push to diversify its pipeline beyond COVID-19 treatments and rebuild its oncology portfolio.
Pfizer Inc. has initiated two significant Phase 1 clinical trials targeting distinct therapeutic areas, marking the pharmaceutical giant's continued efforts to expand its pipeline beyond its COVID-19 franchise. The company announced updates on studies for both kidney disease (搜索) and liver cancer (搜索) treatments, signaling its commitment to addressing unmet medical needs in these challenging therapeutic areas.
Kidney Disease Treatment Breakthrough
Pfizer has launched a Phase 1 clinical study evaluating PF-07985631 (搜索), a potential treatment for IgA nephropathy (搜索), a kidney disease (搜索) with limited therapeutic options. The randomized, multi-center, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of the experimental drug in healthy adult participants.
The intervention involves PF-07985631 (搜索) administered via subcutaneous injection, compared against placebo to determine safety and efficacy. The study follows an interventional, randomized, parallel assignment model with double masking for both participants and investigators, focusing on basic science to understand the drug's pharmacokinetics and safety profile.
The kidney disease (搜索) trial is scheduled to begin on November 14, 2025, with primary completion and estimated completion dates yet to be determined. The latest update was submitted on December 3, 2025, indicating active preparation for the study launch.
Liver Cancer Pipeline Expansion
In oncology, Pfizer is advancing PF-08634404 (搜索) through a Phase 1b/2 study for unresectable locally advanced or metastatic hepatocellular carcinoma (搜索). The open-label trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy of the biological drug as both monotherapy and in combination therapy.
The liver cancer (搜索) study tests PF-08634404 (搜索), delivered by intravenous infusion and designed to target cancer cells in hepatocellular carcinoma (搜索). The trial examines both standalone treatment and combination with ipilimumab, an existing antibody used in cancer care, to determine if the combination delivers stronger and more durable responses than the new drug alone.
This interventional trial uses a randomized design in the Phase 2 portion, where participants are assigned to either PF-08634404 (搜索) alone or the combination with ipilimumab. The study employs a sequential model, testing doses and groups step by step, starting with safety assessments. As an open-label design, both doctors and patients know which treatment is being administered.
Strategic Pipeline Development
The liver cancer (搜索) trial is currently recruiting participants, with initial submission to the registry on November 7, 2025, and a recent update posted on December 16, 2025. While primary and final completion dates are not yet posted, safety and dose-finding readouts are expected before meaningful efficacy data, which are anticipated several years away.
These developments represent Pfizer's strategic push to rebuild its oncology pipeline and diversify beyond its maturing COVID franchise. The kidney disease (搜索) study explores a new therapeutic avenue for a condition with limited treatment options, while the liver cancer (搜索) program targets patients with few available therapies.
For the liver cancer (搜索) indication, PF-08634404 (搜索) will face competition from established players including Roche, Bayer, and Merck (搜索), which already market liver cancer treatments. The experimental drug would need to demonstrate clear advantages in safety or survival to gain market share in this competitive landscape.
Both trials carry the inherent high development risks associated with early-stage pharmaceutical research, but they signal Pfizer's commitment to addressing significant unmet medical needs in nephrology and oncology.